Bank of New York Mellon Corp acquired a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 298,866 shares of the company's stock, valued at approximately $6,333,000. Bank of New York Mellon Corp owned about 0.26% of Immunome at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in IMNM. Renaissance Technologies LLC purchased a new stake in Immunome during the first quarter valued at about $1,507,000. California State Teachers Retirement System boosted its stake in shares of Immunome by 66.3% in the first quarter. California State Teachers Retirement System now owns 111,444 shares of the company's stock valued at $2,437,000 after purchasing an additional 44,432 shares during the period. Nan Fung Trinity HK Ltd. boosted its position in Immunome by 20.7% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company's stock valued at $15,349,000 after buying an additional 122,450 shares during the last quarter. Bank of America Corp DE grew its stake in Immunome by 285.6% during the 1st quarter. Bank of America Corp DE now owns 781,607 shares of the company's stock valued at $17,094,000 after purchasing an additional 578,890 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company's stock worth $129,705,000 after buying an additional 1,144,788 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Immunome
In other news, CFO Max Rosett sold 60,000 shares of the company's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the completion of the transaction, the chief financial officer owned 54,037 shares of the company's stock, valued at approximately $985,094.51. This represents a 52.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $19.85, for a total value of $1,091,750.00. Following the completion of the transaction, the insider directly owned 15,805 shares of the company's stock, valued at approximately $313,729.25. This trade represents a 77.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 682,310 shares of company stock worth $15,675,566. 7.21% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several analysts have issued reports on IMNM shares. Weiss Ratings restated a "sell (d-)" rating on shares of Immunome in a research note on Friday, July 17th. Truist Financial lifted their target price on Immunome from $37.00 to $38.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. HC Wainwright reaffirmed a "buy" rating on shares of Immunome in a research note on Thursday, July 9th. Wedbush raised their target price on Immunome from $31.00 to $35.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. Finally, Leerink Partners reduced their price objective on Immunome from $37.00 to $33.00 and set an "outperform" rating for the company in a research note on Friday, May 15th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $34.64.
Check Out Our Latest Research Report on Immunome
Immunome Stock Down 1.5%
Shares of IMNM stock opened at $26.76 on Friday. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $30.06. The business's 50 day moving average is $24.96 and its two-hundred day moving average is $22.57. The company has a market cap of $3.04 billion, a PE ratio of -10.58 and a beta of 2.13.
Immunome (NASDAQ:IMNM - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). As a group, equities analysts expect that Immunome, Inc. will post -2.38 EPS for the current fiscal year.
About Immunome
(
Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Further Reading
Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
